CADTH has issued positive draft recommendation for RADICAVA® Oral Suspension!

The Canadian Drug Expert Committee (CDEC) recommends reimbursement for RADICAVA® Oral Suspension for treating patients with amyotrophic lateral sclerosis (ALS), with conditions, and with the same criteria as the IV formulation.

You can find the CADTH draft recommendation for RADICAVA® Oral Suspension at their website: https://www.cadth.ca/edaravone-0